Drug intelligence / Profile preview

A1-061

Development stage: Unknown
Lead developer: OncoC4
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

A1-061 is a monoclonal antibody targeting Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), currently under development by AcroImmune for the treatment of various tumors. As a checkpoint inhibitor, A1-061 is designed to block the inhibitory signaling pathway mediated by CTLA-4 on T cells, thereby enhancing the immune system's ability to recognize and eliminate cancer cells. The drug has progressed into Phase 1/2 clinical trials, with early-stage clinical studies being conducted in Australia.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on A1-061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A1-061.

Explore the full profile